Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial
Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial
Regenxbio正在招募新的受试者参加1/2期肌萎缩性依赖性肌肉萎缩症试验。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册